Table 2.
Prevalence of Renal Impairmenta according to Tenofovir Exposure at Different Weeks of Antiretroviral Therapy.
| Weeks of ART | All Patients | Tenofovir-Exposed Patients | Tenofovir-Unexposed Patients | P Value (a) versus (b) | |||
|---|---|---|---|---|---|---|---|
| Number of Patients with Renal Impairment/Number of Exposed | Percentage (95% CI) of Patients with Renal Impairment | Number of Patients with Renal Impairment/Number of Exposed | Percentage (95% CI) of Patients with Renal Impairment (a) | Number of Patients with Renal Impairment/Number of Exposed | Percentage (95% CI) of Patients with Renal Impairment (b) | ||
| 24 | 348/3806 | 9.14 (8.22-10.06) | 168/1635 | 10.28 (8.87-11.74) | 180/2171 | 8.29 (7.19-9.53) | .46 |
| 48 | 565/3784 | 14.93 (13.85-16.12) | 176/1370 | 12.85 (11.1-14.82) | 389/2414 | 16.11 (14.71-17.48) | .03 |
| 96 | 597/2802 | 21.31 (19.74-22.91) | 387/1105 | 35.02 (32.4-37.92) | 210/1697 | 12.37 (10.84-14.02) | <.001 |
| 144 | 860/3244 | 26.51 (24.97-28.14) | 574/1267 | 45.3 (42.62-48.38) | 286/1977 | 14.47 (12.85-16.08) | <.001 |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; eGFR, estimated glomerular filtration rate; SCr, serum creatinine.
a Patient met 1 or more of the defined criteria for renal impairment based on eGFR <60 mL/min/1.73 m2 or a doubling of SCr from baseline.